Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LEXG-Lexicon Genetics -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (18)	11/14/2000 6:39:32 PM
From: JFitnich	Read Replies (1) \| Respond to of 254

The interesting item here is the TLRK deal with LEXG. Interesting relationship dynamic between TLRK and DGEN. As you probably know, most of the top management in both DGEN and TLRK are ex-Genentech. I'm guessing TLRK has had the best look at both of them. DGEN was pretty adamant on the Conf Call that they were not using positive negative selection and thus they were not infringing on LEXG's patent estate. They also indicated that BMY passed on DGEN because of price. They later signed with LEXG as your post indicates. Disclosure: I own both TLRK and LEXG. I am looking closely at DGEN. I may wait for the lockup period on DGEN as I did with LEXG. I'm not qualified to pick between the two and will probably end up buying both. You raise a good point about the cash levels. They have enough to fight a long time. This latest release is certainly interesting. JF